Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study

This is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), aiming to evaluate the efficacy and safety of neoadjuvant adebrelimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC).

Trial Details

NCT ID
NCT07437898
Phase
PHASE2
Sponsor
The Affiliated Hospital of Putian University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Adebrelimab
  • chemotherapy
Locations (sample)
  • Putian, Fujian, China|25.43944,119.01028

Key Eligibility Criteria

  • Provided written informed consent and voluntarily enrolled in this study;
  • Aged 18-75 years, male or female;
  • Histologically or cytologically confirmed esophageal squamous cell carcinoma (ESCC);
  • Clinical stage: cT1b-cT2N+M0 or cT3-cT4a any N M0;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →